| Literature DB >> 33442456 |
Ricardo U Macías-Rodríguez1, Astrid Ruiz-Margáin1, Berenice M Román-Calleja1, May E Espin-Nasser1, Nayelli C Flores-García1, Aldo Torre1, Gretel Galicia-Hernández1, Silvia L Rios-Torres1, Gabriela Fernández-Del-Rivero1, Arturo Orea-Tejeda2, Oscar A Lozano-Cruz3.
Abstract
BACKGROUND: The implementation of nutritional strategies targeting several variables at once could benefit patients with cirrhosis. Non-alcoholic beer has different compounds that exert antioxidant, anti-inflammatory and nutritional properties. AIM: To evaluate the effect of diet + exercise and non-alcoholic beer on nutritional status, endothelial function and quality of life in patients with cirrhosis.Entities:
Keywords: Antioxidants; Cirrhosis; Diet; Hops; Portal hypertension; Sarcopenia
Year: 2020 PMID: 33442456 PMCID: PMC7772724 DOI: 10.4254/wjh.v12.i12.1299
Source DB: PubMed Journal: World J Hepatol
Figure 1CONSORT enrollment diagram.
Baseline characteristics of the study population
|
|
|
|
|
|
| Sex | 26 (60.5)/17 (39.5) | 12 (46.2)/9 (52.9) | 14 (53.8)/8 (47.1) | 0.663 |
| Age (yr) | 53.5 ± 7.8 | 53.7 ± 8.2 | 53 ± 7.6 | 0.768 |
| BMI (kg/m2) | 29.5 ± 4.2 | 29.2 ± 3.7 | 29.8 ± 4.8 | 0.635 |
| Etiology of cirrhosis | ||||
| HCV | 14 (32.6) | 6 (28.5) | 8 (36.4) | 0.063 |
| AIH | 9 (20.9) | 3 (14.3) | 6 (27.3) | |
| NAFLD | 8 (18.6) | 5 (23.8) | 3 (13.6) | |
| Others | 12 (27.9) | 7 (33.4) | 5 (22.7) | |
| History of complications [ | ||||
| Variceal bleeding | 2 (4.7) | 2 (9.5) | 0 (0) | 0.233 |
| Encephalopathy | 1 (2.3) | 0 (0) | 1 (4.5) | 0.500 |
| Ascites | 5 (11.6) | 3 (14.3) | 2 (9.1) | 0.664 |
| Child-Pugh stage | ||||
| A | 38 (88.4) | 20 (95.2) | 18 (81.9) | 0.345 |
| B | 5 (11.6) | 1 (4.8) | 4 (18.1) | |
| Child-Pugh | 5 (5-6) | 5 (5-6) | 5 (5-6) | 0.617 |
| MELD score | 8 (7-10) | 8 (7.5-9.5) | 8.5 (7-10) | 0.524 |
| Biochemical parameters | ||||
| TB (mg/dL) | 1.19 (0.82-1.95) | 1.15 (0.75-1.44) | 1.28 (0.85-2.11) | 0.284 |
| ALT (U/L) | 43 (26-77) | 43 (30-86.5) | 43.1 (20.75-77) | 0.882 |
| AST (U/L) | 48 (37-93) | 47 (40-80) | 50.5 (32-98) | 0.881 |
| AP (mg/dL) | 142.2 ± 57.7 | 123.7 ± 44.1 | 159.8 ± 64.4 | 0.039 |
| Albumin (g/dL) | 4.0 (3.6-4.2) | 4.1 (3.8-4.3) | 3.9 (3.3-4.1) | 0.170 |
| Leukocytes (K/µL) | 4.2 (3.7-5.3) | 4.0 (3.7-5.15) | 4.75 (3.725-5.925) | 0.233 |
| Platelets (K/µL) | 80 (62-125) | 77 (61.5-125) | 93.5 (63.5-125) | 0.520 |
| Hemoglobin (g/dL) | 14.1 ± 1.94 | 14.2 ± 3.3 | 14.0 ± 2.4 | 0.755 |
| INR | 1.1 (1.1-1.2) | 1.1 (1.1-1.2) | 1.1 (1.1-1.2) | 0.870 |
| Glucose (mg/dL) | 91 (83-103) | 94 (83.5-109) | 91 (81-100.5) | 0.882 |
| Creatinine (mg/dL) | 0.72 (0.63-0.80) | 0.72 (0.60-0.81) | 0.71 (0.64-0.79) | 0.892 |
| Sodium (mmol/L) | 139 (137-141) | 140 (137.5-141) | 138 (137-140.2) | 0.290 |
| Potassium (mmol/L) | 4.08 ± 0.32 | 4.0 ± 0.37 | 4.1 ± 0.25 | 0.198 |
| CO2 (mmol/L) | 24 (21-26) | 23.0 (21.5-26) | 24.5 (21-27.25) | 0.518 |
Other etiologies included cryptogenic, primary biliary cholangitis and overlap syndrome (HAI/CBP). Data reported as mean ± standard deviation or median (p25-p75), according to the distribution of the data, or absolute frequency (percentage %). BMI: Body mass index; HCV: Hepatitis C virus; AIH: Autoimmune hepatitis; NAFLD: Non-alcoholic fatty liver disease; TB: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AP: Alkaline phosphatase; INR: International normalized ratio.
Changes in clinical and biochemical parameters
|
|
|
|
| |||
|
|
|
|
|
|
|
|
| Number of daily steps | 8718 ± 2998 | 11391 ± 4298 | 0.000 | 8533 ± 4072 | 11142 ± 4055 | 0.000 |
| PHES score | -1 ± 2.2 | 0 ± 2.2 | 0.130 | -1 ± 2.1 | 0 ± 2.3 | 0.179 |
| CFF (Hz) | 43.9 ± 7.1 | 45.5 ± 5.8 | 0.238 | 44.5 ± 8.1 | 47.2 ± 6.4 | 0.174 |
| TB (mg/dL) | 1.15 (0.75-1.44) | 1.12 (0.85-1.28) | 0.985 | 1.28 (0.85-2.11) | 1.13 (0.8-1.865) | 0.068 |
| ALT (U/L) | 43 (30-86.5) | 41 (23.5-71) | 0.024 | 43.1 (20.75-77) | 36 (20.25-67.5) | 0.198 |
| AST (U/L) | 47 (40-80) | 45 (29.5-53.5) | 0.015 | 50.5 (32-98) | 44 (28-75.75) | 0.035 |
| Alkaline phosphatase (U/L) | 123.7 ± 44.1 | 105 (79.50-139) | 0.408 | 159.8 ± 64.4 | 159.9 ± 79.3 | 0.988 |
| Albumin (g/dL) | 4.1 (3.8-4.3) | 4 (3.75-4.2) | 0.668 | 3.9 (3.3-4.1) | 3.9 (3.475-4.3) | 0.501 |
| Leukocytes (K/µL) | 4.0 (3.7-5.15) | 3.9 (3-5) | 0.984 | 4.75 (3.725-5.925) | 4.9 (3.62-6.1) | 0.515 |
| Platelets (K/µL) | 77 (61.5-125) | 75 (59-106.5) | 0.278 | 93.5 (63.5-125) | 107 (78.5-150.25) | 0.046 |
| Hemoglobin (g/dL) | 14.2 ± 3.3 | 14.17 ± 1.52 | 0.968 | 14.0 ± 2.4 | 14.25 ± 2 | 0.834 |
| INR | 1.1 (1.1-1.2) | 1.1 (1.1-1.2) | 0.414 | 1.1 (1.1-1.2) | 1.1 (1.0-1.2) | 0.166 |
| Glucose (mg/dL) | 94 (83.5-109) | 88 (82-108) | 0.145 | 91 (81-100.5) | 87.5 (84.75-96.25) | 0.615 |
| Creatinine (mg/dL) | 0.72 (0.60-0.81) | 0.71 (0.6-0.84) | 0.403 | 0.71 (0.64-0.79) | 0.70 (0.62-0.79) | 0.723 |
| Na (mmol/L) | 140 (137.5-141) | 140 (139-141.5) | 0.118 | 138 (137-140.2) | 140 (138.5-141) | 0.061 |
| K (mmol/L) | 4.0 ± 0.37 | 4.16 ± 0.38 | 0.195 | 4.1 ± 0.25 | 4.2 ± 0.37 | 0.078 |
| CO2 (mmol/L) | 23.0 (21.5-26) | 24.0 (22-26) | 0.850 | 24.5 (21-27.25) | 24 (22.95-26.15) | 0.304 |
Data reported as mean ± standard deviation, or median (p25-p75), according to the distribution of the data. PHES: Psychometric hepatic encephalopathy score; CFF: Critical flicker frequency; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; INR: International normalized ratio.
Figure 2Changes in endothelial dysfunction at baseline and final evaluations. The figure shows the percentage of patients with endothelial dysfunction at baseline and final evaluation.
Endothelial function and hemodynamic variables
|
|
|
|
| |||
|
|
|
|
|
|
| |
| AUC | 103.13 (92.55-107.15) | 93.15 (86.53-99.61) | 0.021 | 98.04 (92.17-102.35) | 93.62 (85.06-99.60) | 0.046 |
| Systolic pressure (mmHg) | 120 (110-130) | 120 (120-129) | 0.418 | 120 (110-120) | 113 (110-120) | 0.513 |
| Diastolic pressure (mmHg) | 80 (60-80) | 80 (60-80) | 0.862 | 70 (67.5-80) | 70 (60-80) | 0.385 |
| Mean arterial pressure | 90 (76.693.3) | 93.3 (78.3-96) | 0.729 | 86.6 (82.5-93.3) | 83.3 (76.6-90.5) | 0.385 |
| Heart rate (bpm) | 62 (60-72.7) | 63 (60.25-80) | 0.079 | 69 (61.5-75.2) | 67 (61.5-71.25) | 0.235 |
Data reported as median (p25-p75). AUC: Area under the curve.
Figure 3Area under the curve showing the behavior of endothelial function at baseline and final evaluations in the two groups. A: Control; B: Intervention. Data are presented as median (IQR). MAT: Maximal amplitude time; TT: Total time.
Changes in nutritional parameters at baseline and final evaluation
|
|
|
|
| |||
|
|
|
|
|
|
| |
| Phase angle | 6.0 ± 0.7 | 5.9 ±0.6 | 0.427 | 5.8 ± 0.7 | 5.9 ± 0.7 | 0.198 |
| MAMC (cm2) | 24.1 ± 3.1 | 23.9 ± 3.5 | 0.462 | 23.5 ± 3.4 | 23.6 ± 3.9 | 0.783 |
| TST (mm) | 25.5 ± 7.9 | 24.7 ± 4.5 | 0.397 | 26.6 ± 6.7 | 26.9 ± 6.3 | 0.782 |
| Thigh circumference (cm) | 53.1 ± 6.5 | 52.9 ± 7.0 | 0.758 | 51.7 ± 6.4 | 53.1 ± 4.6 | 0.033 |
| Handgrip strength (kg) | 19.9 ± 11.5 | 21 ± 11.2 | 0.121 | 18.1 ± 10.3 | 19.9 ± 10.5 | 0.048 |
| Sit-To-Stand test (s) | 24.2 ± 4.4 | 20.9 ± 6.9 | 0.001 | 23.3 ± 3.9 | 21.0 ± 6.2 | 0.045 |
Data reported as mean ± standard deviation. MAMC: Mid-arm muscle circumference; TST: Triceps skinfold thickness.
Figure 4Changes in mid-arm muscle circumference percentile throughout the study. Data are presented as mean percentile ± SD. MAMC: Mid-arm muscle circumference.
Changes in quality of life
|
|
|
|
| |||
|
|
|
|
|
|
| |
| CLDQ questionnaire | ||||||
| Abdominal symptoms | 5.4 ± 1.3 | 5.2 ± 0.8 | 0.592 | 5.0 ± 1.5 | 5.1 ± 1.2 | 0.982 |
| Fatigue | 4.7 ± 1.1 | 5.2 ± 0.8 | 0.063 | 4.2 ± 1.2 | 5.1 ± 1.2 | 0.000 |
| Systemic symptoms | 5.6 ± 1.0 | 5.6 ± 0.9 | 0.892 | 4.3 ± 1.2 | 5.0 ± 0.9 | 0.002 |
| Activity | 5.3 ± 1.2 | 5.3 ± 1.3 | 0.892 | 4.8 ± 1.2 | 5.5 ± 1.2 | 0.028 |
| Emotional function | 4.9 ± 0.9 | 5.3 ± 1.1 | 0.056 | 4.3 ± 1.3 | 5.3 ± 1.0 | 0.000 |
| Worry | 5.1 ± 1.1 | 5.3 ± 1.1 | 0.521 | 4.3 ± 1.8 | 5.2 ± 1.8 | 0.002 |
| CLDQ overall score | 5.2 ± 0.8 | 5.4 ± 0.9 | 0.204 | 4.6 ± 1.0 | 5.3 ± 0.8 | 0.001 |
| SF-36 questionnaire | ||||||
| Physical function | 80 (70-90) | 95 (80-95) | 0.005 | 72.5 (65-95) | 87.5 (70-95) | 0.007 |
| Physical role | 75 (25-100) | 100 (50-100) | 0.166 | 62.5 (25 -100) | 75 (25-100) | 0.468 |
| Body pain | 84 (66-90) | 84 (72-90) | 0.341 | 78 (61-84) | 78 (60-84) | 0.725 |
| General health | 40 (37-47) | 47 (35-52) | 0.044 | 40 (25-55) | 42 (32-52) | 0.375 |
| Vitality | 65 (50-70) | 70 (60-75) | 0.453 | 62.5 (50-75) | 70 (50-80) | 0.037 |
| Social function | 100 (75-100) | 88 (75-100) | 0.875 | 75 (63-100) | 88 (75-100) | 0.080 |
| Emotional role | 67 (33-83) | 67 (33-67) | 0.972 | 67 (33-72) | 67 (33-67) | 0.752 |
| Mental health | 72 (68-84) | 84 (64-88) | 0.868 | 76 (64-84) | 82 (68-92) | 0.073 |
Data reported as mean ± standard deviation, or median (p25-p75), according to the distribution of the data. CLDQ: Chronic liver disease questionnaire; SF-36: 36-item short form health survey.